Compare Ares Capital Corporation (ARCC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Ares Capital Corporation trades at $19.96 (market cap $14.34B), while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Ares Capital Corporation pays the higher dividend (9.61%). Which is the better fit depends on your goals.
| ARCC | ZBH | |
|---|---|---|
Market Cap | $14.34B | $18.55B |
Sector | Financials | Health |
52-Week High | $22.68 | $107.71 |
52-Week Low | $17.45 | $79.58 |
Dividend Yield | 9.61% | 0.99% |
Enterprise Value | — | $25.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARCC trades at $19.87, down 0.55% with a bullish technical outlook supported by moving averages. The company reported $1.51B revenue and $1.30B net income for 2025, maintaining an 86.25% profit margin. Recent earnings show slight misses against expectations, but dividend coverage remains stable at 104% with a 9.9% yield. Analyst consensus is strongly bullish with 24 buy ratings and a $19.63 price target.
The stock presents income appeal with its high dividend yield and stable payout history, though recent earnings compression and rising non-accruals to 2.4% signal credit quality concerns. Private credit sector strain and potential rate cuts pose medium-term risks to net investment income, which is 71% variable-rate exposed.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
